Search

Your search keyword '"Pagano C"' showing total 26 results
Start Over Author "Pagano C" Publisher elsevier bv
26 results on '"Pagano C"'

12. Metabolic syndrome in adult patients with Prader–Willi syndrome

Author

Grugni, G., primary, Crinò, A., additional, Bedogni, G., additional, Cappa, M., additional, Sartorio, A., additional, Corrias, A., additional, Di Candia, S., additional, Gargantini, L., additional, Iughetti, L., additional, Pagano, C., additional, Ragusa, L., additional, Salvatoni, A., additional, Spera, S., additional, Vettor, R., additional, Chiumello, G., additional, and Brambilla, P., additional

Published
2013
Full Text
View/download PDF

26. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets

Author

Chiara Piscopo, Maria Proto, Cristina Pagano, Mario Galgani, Donatella Fiore, Maurizio Bifulco, Chiara Laezza, Sara Bruzzaniti, Patrizia Gazzerro, Proto, M. C., Fiore, D., Piscopo, C., Pagano, C., Galgani, M., Bruzzaniti, S., Laezza, C., Gazzerro, P., and Bifulco, M.

Subjects
0106 biological sciences, 0301 basic medicine, viruses, CoV, coronavirus, Review, ZIKV, Zika virus, 01 natural sciences, Biochemistry, chemistry.chemical_compound, MβCD, methyl-β-cyclodextrin, Lipid homeostasis, SARS, Severe Acute Respiratory Syndrome, CMV, human cytomegalovirus, LDL, low-density lipoprotein, MVA, mevalonate, Homeostasis, TMPRSS2, transmembrane protease serine 2, Endothelial dysfunction, Mevalonate pathway inhibitor, PI, phosphatidil-inositol, Hypolipidemic Agents, Hypolipidemic Agent, ACE2, angiotensin converting enzyme 2, SREBP, sterol regulatory element binding protein, HIV, human immunodeficiency virus, Cholesterol, HMGCR, 3-hydroxy-3-methylglutaryl-CoA reductase, WNV, West Nile virus, Mevalonate pathway inhibitors, SARS-CoV-2, Statins, Viral infections, COVID-19, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Mevalonic Acid, Lipid Metabolism, BPs, bisphosphonates, HCV, hepatitis C virus, VZV, Varicella zoster virus, EBOV, Ebola virus, Mevalonate pathway, medicine.symptom, Human, HDL, high-density lipoprotein, FDPS, farnesyl diphosphate synthase, Inflammation, Virus, 03 medical and health sciences, Immune system, Homeostasi, IAV, influenza A virus, medicine, IFN, interferon, Permissive, Mpro, SARS-CoV-2 main protease, business.industry, Statin, Lipid metabolism, Cell Biology, medicine.disease, Lipid homeostasi, COVID-19 Drug Treatment, IL, interleukin, 030104 developmental biology, KSHV, Kaposi's sarcoma-associated herpesvirus, chemistry, Viral infection, MERS, Middle-East Respiratory Syndrome, Immunology, Hydroxymethylglutaryl-CoA Reductase Inhibitor, RSV, respiratory syncytial virus, Treg, T regulatory cells, DENV, Dengue virus, LXR, liver X receptor, business, 010606 plant biology & botany
Abstract

Despite encouraging progresses achieved in the management of viral diseases, efficient strategies to counteract infections are still required. The current global challenge highlighted the need to develop a rapid and cost-effective strategy to counteract the SARS-CoV-2 pandemic. Lipid metabolism plays a crucial role in viral infections. Viruses can use the host lipid machinery to support their life cycle and to impair the host immune response. The altered expression of mevalonate pathway-related genes, induced by several viruses, assures survival and spread in host tissue. In some infections, statins, HMG-CoA-reductase inhibitors, reduce cholesterol in the plasma membrane of permissive cells resulting in lower viral titers and failure to internalize the virus. Statins can also counteract viral infections through their immunomodulatory, anti-inflammatory and anti-thrombotic effects. Beyond statins, interfering with the mevalonate pathway could have an adjuvant effect in therapies aimed at mitigating endothelial dysfunction and deregulated inflammation in viral infection. In this review we depicted the historical and current evidence highlighting how lipid homeostasis and mevalonate pathway targeting represents a valid approach to rapidly neutralize viruses, focusing our attention to their potential use as effective targets to hinder SARS-CoV-2 morbidity and mortality. Pros and cons of statins and Mevalonate-pathway inhibitors have been also dissected.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results